Exicure Inc. (NASDAQ: XCUR) received a notification from NASDAQ on June 5 stating the company does not meet the minimum stockholders' equity requirement of $2.5 million for continued listing on The NASDAQ Capital Market.

The biotechnology company reported stockholders' equity of approximately $2.1 million in its quarterly report for the period ended March 31, 2026. NASDAQ also determined that Exicure does not satisfy alternative listing standards related to market value of listed securities or net income from continuing operations.

The notification does not immediately affect the listing of Exicure's common stock. Under NASDAQ rules, the company has 45 calendar days until July 20, 2026, to submit a compliance plan. If accepted, NASDAQ may grant an extension of up to 180 calendar days from the notice date to regain compliance.

Exicure attributed its financial position partly to executive separation expenses and obligations under consulting arrangements entered before the current management team's appointment. The company stated it has implemented cost-reduction and restructuring initiatives, including terminating substantially all non-essential legacy consulting arrangements.

The company said it intends to submit a compliance plan within the prescribed timeframe and is evaluating alternatives to regain compliance with listing requirements.

Exicure has transitioned from developing nucleic acid therapies to exploring strategic alternatives following restructuring and suspension of clinical activities. In January 2025, the company acquired a clinical-stage biotechnology company developing therapeutics for hematologic diseases.